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Abstract
Background: Most HIV-1-infected patients on effective antiretroviral therapy (ART) with plasma HIV-1 RNA levels below the
detection limits of commercial assays have residual viremia measurable by more sensitive methods. We assessed whether
adding raltegravir lowered the level of residual viremia in such patients.
Methods and Findings: Patients receiving ART who had plasma HIV-1 RNA levels below 50 copies/mL but detectable viremia by
single copy assay (SCA) were randomized to add either raltegravir or placebo to their ART regimen for 12 weeks; patients then
crossed-over to theother therapyfor an additional 12 weeks while continuingpre-study ART. Theprimary endpoint was the plasma
HIV-1 RNA by SCA averaged between weeks 10 and 12 (10/12) compared between treatment groups. Fifty-three patients were
enrolled. The median screening HIV-1 RNA was 1.7 copies/mL. The HIV-1 RNA level at weeks 10/12 did not differ significantly
between the raltegravir-intensified (n=25) and the placebo (n=24) groups (median 1.2 versus 1.7 copies/mL, p=0.55, Wilcoxon
rank sum test), nor did the change in HIV-1 RNA level from baseline to week 10/12 (median 20.2 and 20.1 copies/mL, p=0.71,
Wilcoxon rank sum test). There was also no significant change in HIV-1 RNA level from weeks 10/12 to weeks 22/24 after patients
crossed-over. There was a greater CD4 cell count increase from baseline to week 12 in the raltegravir-intensified group compared
withtheplacebogroup(+42versus244cells/mm
3,p=0.082,Wilcoxonranksumtest),whichreversedafterthecross-over.ThisCD4
cell count change was not associated with an effect of raltegravir intensification on markers of CD4 or CD8 cell activation in blood.
Conclusion: In this randomized, double-blind cross-over study, 12 weeks of raltegravir intensification did not demonstrably
reduce low-level plasma viremia in patients on currently recommended ART. This finding suggests that residual viremia
does not arise from ongoing cycles of HIV-1 replication and infection of new cells. New therapeutic strategies to eliminate
reservoirs that produce residual viremia will be required to eradicate HIV-1 infection.
Trial Registration: ClinicalTrials.gov NCT00515827
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Although currently recommended antiretroviral therapy (ART)
lowers plasma HIV-1 RNA levels to below the detection limit of
commercial assays (generally ,50 copies/mL), most patients have
persistent low-level viremia when tested with more sensitive methods
[1]. In fact, using a real-time PCR assay that detects a single copy of
HIV-1 RNA, more than 80% of patients on combination ART had
viremia of one copy/mL or more [2]. This residual viremia does not
measurably decay after up to 7 years of ART [3].
The causes and clinical implications of persistent low-level
viremia in patients on ART are controversial (reviewed in [4]).
Residual plasma viremia may arise from ongoing cycles of viral
replication and infection of new cells, virus release from stable
reservoirs, or both. If persistent viremia in patients who are
receiving ART is mainly due to viral replication, intensifying
therapy by adding a new, potent antiretroviral drug that blocks
new cycles of replication should reduce residual viremia and
prevent repletion of viral reservoirs, a crucial step toward HIV-1
eradication. Alternatively, if residual viremia is primarily due to
HIV-1 release from stable reservoirs, such as latently infected
resting CD4 memory cells or other long-lived cells, then treatment
intensification with drugs that block only new cycles of viral
replication would not be expected to reduce persistent viremia.
Indeed, prior intensification studies of patients on suppressive
three-drug antiretroviral regimens did not observe reductions in
plasma HIV-1 RNA levels after the addition of antiretroviral drugs
that block new replication cycles, including inhibitors of reverse
transcriptase (RT), protease, and integrase [5,6]. However, these
studies were small, single-arm trials of short duration that were not
randomized or placebo-controlled and had limited power to detect
changes in residual viremia. Larger, randomized, and placebo-
controlled trials are needed to more definitely assess the impact of
treatment intensification on residual viremia.
Raltegravir, the first U.S. Food and Drug Administration-
approved HIV-1 integrase inhibitor, is an attractive agent to study
the effects of treatment intensification on residual viremia. The
drug is a potent inhibitor of HIV-1 replication [7,8] and blocks the
virus through a mechanism different from those of other
commonly prescribed antiretroviral medications, such as RT
and protease inhibitors. If low-level residual viremia is the result of
incomplete inhibition of HIV-1 replication by RT and protease
inhibitors, then blocking a third viral enzyme with raltegravir
might reduce HIV-1 RNA levels.
To assess whether raltegravir intensification lowers residual
viremia in patients on combination ART, we conducted a multi-
center randomized, double-blind placebo-controlled cross-over
study (AIDS Clinical Trials Group study A5244).
Methods
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study (Text S1 and S2) was
approved by the Institutional Review Boards of all institutions at
which patients were enrolled. All patients provided written
informed consent for study participation, the collection of samples
and subsequent analysis. The NCT number for this study is
NCT00515827.
The main inclusion criteria for the study (Text S1) were: (1)
HIV-1 infected adults receiving ART for at least 12 months with
two or more nucleoside reverse transcriptase inhibitors (NRTI)
and either a ritonavir-boosted protease inhibitor (PI) or a non-
nucleoside reverse transcriptase inhibitor (NNRTI); (2) plasma
HIV-1 RNA levels below limits of detection for $6 months using
commercial assays; and (3) CD4 cell count $200/mm
3.
Participants were also required to have documentation of a pre-
ART HIV-1 RNA level of .100,000 copies/mL because
detectable residual viremia is more likely in individuals with
higher pre-treatment HIV-1 RNA levels [2]. Patients were
excluded if they had a history of documented virologic failure
while on ART. All participants were integrase inhibitor-naı ¨ve.
Patients who met the above criteria underwent testing with a
real-time PCR assay that can detect a single copy of HIV-1 RNA
in a plasma sample (Figure 1). The quantification limit is
determined by the volume of plasma tested. Approximately 50%
of the plasma volume is used for HIV-1 RNA quantification and
the remainder for assay controls; e.g. if 10 mL of plasma is tested,
the lower limit of quantification (LLQ) is 0.2 copies/mL [9]. At the
time of screening, the plasma volume assayed was $7 mL in 97%
of patients and $10 mL in 75% of patients. Participants who had
detectable screening HIV-1 RNA measured by this single copy
assay (SCA) were eligible for the study.
Eligible patients were randomized with equal probability to
either immediate-intensification (group A) or delayed-intensifica-
tion (group B) with raltegravir, using permuted blocks, stratified by
whether they were on a PI- or NNRTI-containing entry regimen
(Figure 2). Participants in the immediate-intensification group
(raltegravir-first) added raltegravir 400 mg twice daily to their
entry regimen at week 0. At week 12, participants in this group
stopped raltegravir and added matching placebo twice daily for 12
more weeks. Patients in the delayed intensification group (placebo-
first) added placebo twice daily to their entry regimen at week 0.
At week 12, those in this group stopped placebo and added
raltegravir 400 mg twice daily for 12 more weeks. The planned
duration of this double-blind study was 24 weeks. To estimate
participant adherence to study drug, pill counts were performed at
weeks 2, 4, 10, 12, 14, 16, 22, and 24. Adverse events were graded
using the DAIDS Toxicity Grading Tables (available at http://rsc.
tech-res.com/safetyandpharmacovigilance/) on a scale of 1 to 4
that signifies severity ranging from mild to life-threatening.
SCA testing was performed at pre-entry, entry, and weeks 10,
12, 22, and 24. Samples from these time points were assayed in a
batch for each patient (i.e., all samples from an individual
participant were assayed in a single test run). The plasma volume
assayed was $7m Li n$90% of samples (range at the different
time points, 90%–94%) and $10 mL in .83% of samples (range
at the different time points, 84%–94%). The HIV-1 RNA log10
copies/mL values by SCA were averaged at pre-entry and entry
(baseline [average of the pre-entry and entry measurements]),
weeks 10 and 12 (10/12), and weeks 22 and 24 (22/24). CD4 and
CD8 cell counts were assessed by flow cytometry at pre-entry and
entry (the baseline value was the average of the two measurements)
and again at weeks 12 and 24. CD4 and CD8 cell activation in the
blood was assessed on cryopreserved cells at pre-entry and entry
(the baseline value was the average of the two measurements) and
at weeks 12 and 24. The percentage of CD4 and CD8 cells that
expressed the activation markers CD38 and human leukocyte
antigen (HLA)-DR was determined using phycoerythrin-conju-
gated anti-CD38, fluorescein isothiocyanate–conjugated anti-
HLA–DR, allophycocyanin-conjugated anti-CD4, and peridinin
chlorophyll protein-conjugated anti-CD8 monoclonal antibodies
and analyzed by flow cytometry.
The primary objective of the study was to compare the HIV-1
RNA level by SCA at weeks 10/12 in patients who added
raltegravir to a PI- or NNRTI-containing regimen to the level in
patients who added placebo to a PI- or NNRTI-containing
regimen. We conducted an on-treatment analysis and excluded
patients who had confirmed virologic rebound to .50 copies/mL
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participants (25 in each group). From prior data on assay and
biologic variation in residual HIV-1 RNA levels [2], we estimated
that 18 evaluable participants in each treatment group would
provide 80% power to detect a 0.5 log10 difference (1 standard
deviation effect size) in the HIV-1 RNA level at weeks 10/12
between the two treatment groups using a Wilcoxon rank-sum
two-sided test at a 0.05 level. We increased the target enrollment
to 25 in each group with the expectation that some participants
would discontinue study drug prior to week 12 and that treatment
intensification might increase the proportion of participants who
have HIV-1 RNA levels below the LLQ by SCA at weeks 10/12,
which would affect statistical power. When averaging the week 10
and 12 measurements, if one or both measurements were below
the SCA lower assay limits, the LLQ was used to compute the
average and the primary endpoint was treated as below the
averaged value. The primary endpoint was analyzed using the
censored-data version of the Wilcoxon rank-sum test, which
accommodates the fact that participants had different SCA lower
limits due to varying plasma volumes. For analyses of secondary
endpoints (such as the change in HIV-1 RNA value by SCA, CD4
and CD8 cell counts, and activation markers), treatment arms
were compared using exact Wilcoxon rank sum tests for
continuous endpoints or Fisher’s exact tests for proportions. The
within-participant effect of intensification was tested by Wilcoxon
signed rank test. Confidence intervals (CIs) were estimated using
Hodges and Lehmann method. Associations between responses
and predictors were assessed using rank-based Spearman corre-
lations. Reported p-values were two-sided without adjustment for
multiple comparisons.
Results
Baseline Characteristics
One hundred twenty-five patients were screened for the study, of
whom 75 (60%) had detectable plasma HIV-1 RNA by SCA
(Figure 1). Fifty-three patients from 19 different clinical research
sitesenrolled inthe randomizedclinicaltrial. Ofthe22patientswith
Figure 1. Participant disposition.
doi:10.1371/journal.pmed.1000321.g001
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(most commonly because a pre-ART HIV-1 RNA value was not
available orthepatientdidnototherwisemeet theeligibility criteria)
and 11 did not enroll for other reasons (in most cases the reason was
not specified). There were no significant differences in baseline
characteristics (age, race, sex, screening CD4 cell count, entry
regimen, or time since first undetectable HIV-1 RNA value)
between the 22 patients with a detectable HIV-1 RNA by SCA who
did not enroll and the 53 patients who enrolled.
The baseline characteristics of the 53 patients who enrolled in
the study are summarized in Table 1. The median age was 49
years and 91% were male. Sixty-six percent of patients were on an
NNRTI-containing regimen and 34% were on a PI-containing
regimen. The baseline CD4 cell count was 589/mm
3, and the
median time since the first undetectable HIV-1 RNA level on a
commercial assay was 5.5 years. The median (quartile [Q] 1, Q3)
screening HIV-1 RNA level by SCA was 1.7 copies/mL (0.6, 2.9).
Participants in the raltegravir-first and placebo-first groups were
well-balanced with respect to these baseline characteristics. The
median screening HIV-1 RNA by SCA was 1.2 copies/mL in the
raltegravir-first group and 1.9 copies/mL in the placebo-first
group; the interquartile ranges for the median HIV-1 RNA values
in the two groups overlap (Table 1). In addition, even though all
participants had a detectable HIV-1 RNA by SCA at screening,
22% had a value below the lower limits of quantification at either
study entry or pre-entry; there was no statistically significant
difference in the frequency of this finding between the two study
groups.
Figure 2. Study schema.
doi:10.1371/journal.pmed.1000321.g002
Table 1. Baseline characteristics.
Characteristic
Overall
(n=53)
Raltegravir-First (Group A)
(n=27)
Placebo-First (Group B)
(n=26)
Age, median (years) 49 51 47
Male sex (%) 48 (91%) 24 (89%) 24 (92%)
Race/ethnicity
White non-Hispanic 36 (68%) 20 (74%) 16 (62%)
Black non-Hispanic 9 (17%) 5 (19%) 4 (15%)
Hispanic 7 (13%) 2 (7%) 5 (19%)
Not-reported 1 (2%) 0 (0%) 1 (4%)
Background entry regimen
PI-containing 18 (34%) 9 (33%) 9 (35%)
NNRTI-containing 35 (66%) 18 (67%) 17 (65%)
Baseline CD4 count (cells/mm
3), median (Q1, Q3) 589 (452, 751) 538 (401, 717) 613 (454, 833)
Years since first undetectable HIV-1 RNA value, median (Q1, Q3) 5.5 (3.5, 7.0) 4.8 (3.2, 7.9) 5.7 (3.7, 7.0)
Screening HIV-1 RNA by SCA (copies/mL), median (Q1, Q3) 1.7 (0.6, 2.9) 1.2 (0.2, 3.1) 1.9 (0.8, 2.9)
Quartile (Q)1 and Q3 are 25
th and 75
th percentiles. NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SCA, single-copy assay.
doi:10.1371/journal.pmed.1000321.t001
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Of the 53 patients who initiated study treatment, 49 (92%)
contributed data to the primary endpoint at weeks 10/12 and 46
(87%) completed all 24 weeks of the study treatment (Figure 1). In
those who had pill counts to estimate adherence, we found that the
average adherence across participants ranged from 94% to 97% at
different study time points. One participant in each group stopped
treatment because of confirmed virologic failure (2 consecutive
HIV-1 RNA levels .50 copies/mL); both had HIV-1 RNA levels
of ,250 copies/mL and subsequently achieved a HIV-1 RNA
,50 copies/mL without changing their entry regimen (one
participant had genotypic resistance testing performed on samples
drawn during the times he had detectable viremia, but the virus
did not have integrase gene mutations or any other new resistance
mutations). The rate of premature study discontinuation was not
appreciably different between the two treatment groups (two
participants in the raltegravir-first group, one in the placebo-first
group). There was no statistically significant difference between the
groups in the rate of grade 2 or higher signs and symptoms or
grade 3 or higher lab abnormalities. Overall, the study drug was
well-tolerated.
Effect of Raltegravir Intensification on Plasma HIV-1 RNA
Level
The primary objective of the study was to compare the HIV-1
RNA level by SCA at weeks 10/12 in participants who added
raltegravir to a PI- or NNRTI-containing regimen to the level in
those who added placebo to a PI- or NNRTI-containing regimen.
The average HIV-1 RNA level at week 10/12 did not differ
significantly between the raltegravir-intensified (n=25) and the
placebo group (n=24): median 1.2 (0.1 log10) versus 1.7 (0.2 log10)
copies/mL (p=0.55, Wilcoxon rank sum test, 95% CI for the
difference between the groups: 20.4 log10 to 0.3 log10 copies/mL)
(Figure 3A). A similar result was obtained in an intent-to-treat
analysis, which included all participants with week 10/12 data
regardless of treatment status or virologic failure (n=51). In the
intent-to-treat analysis, the median HIV-1 RNA at week 10/12 in
the raltegravir-first group was 1.2 (0.1 log10) copies/mL and in the
placebo group was 1.7 (0.2 log10) copies/mL; there was no
statistically significant difference between the two groups (p=0.73,
Wilcoxon rank sum test, 95% CI for the difference between the
groups: 20.4 to 0.4 log10 copies/mL). The absence of a
demonstrable difference in HIV-1 RNA level at week 10/12
between the two treatment groups was also seen in planned
sensitivity analyses that adjusted for ART regimen at entry,
baseline HIV-1 RNA by SCA and/or baseline CD4 cell count
(using regression models for censored data) (p-values 0.71 to 0.81,
Wald test, data not shown).
We also assessed the difference between the pre-intensification
and post-intensification SCA values in the two treatment groups.
The change in HIV-1 RNA from baseline to weeks 10/12 did not
differ significantly between the two treatment groups (median
20.2 and 20.1 copies/mL, p=0.71, Wilcoxon rank sum test) (for
this comparison, measurements below the LLQ were imputed a
value of the LLQ divided by 2) (Figure 3B). The proportion of
patients who had one or more HIV-1 RNA levels below the LLQ
at week 10/12 did not differ between the two groups (20% versus
13%, p=0.70, Fisher’s exact test). In a protocol-specified
secondary analysis, we also evaluated the change in HIV-1 RNA
level from the pre-intensification level (for the raltegravir-first
group: average of pre-entry and entry values; for the placebo-first
group: average of week 10 and 12 values) to the post-
intensification level (raltegravir-first group: weeks 10/12; placebo-
first group: weeks 22/24). The median change in HIV-1 RNA
level from pre-intensification to post-intensification was 0.0 (20.07
log10) copies/mL (95% CI of 20.5 to 0.3 copies/mL or 20.1 to
0.1 log10 copies/mL). That is, we can exclude, with 95%
confidence, a median decline from baseline HIV-1 RNA during
intensification of more than 24% (.0.1 log10 copies/mL). In our
study population, we can exclude a median reduction in HIV-1
RNA during intensification of more than 0.5 copies/mL. The
proportion of participants who had either an increase or no
change versus a decrease in HIV-1 RNA levels during the
intensification period did not differ significantly between treatment
groups (unpublished data).
In addition, the cross-over design allowed us to evaluate
whether there was an increase in HIV-1 RNA level after
discontinuation of raltegravir by patients in the raltegravir-first
group, or a decrease in HIV-1 RNA level after addition of
raltegravir by those in the group that received placebo first. There
was no significant change in HIV-1 RNA level after participants
crossed-over from raltegravir to placebo or from placebo to
raltegravir (unpublished data).
Effect of Raltegravir Intensification on CD4 and CD8 Cell
Counts
We also examined the effect of raltegravir intensification on
CD4 and CD8 cell counts, which were measured at baseline and
at weeks 12 and 24 (Table 2). There was a greater CD4 count
increase from baseline to week 12 in the raltegravir-first group
compared with the placebo-first group (median +42 cells/mm
3 vs.
244 cells/mm
3), but this difference was not statistically significant
(p=0.082, Wilcoxon rank sum test). After the cross-over, the
change in CD4 cell count reversed in the two groups: the CD4
count in the group that switched to placebo dropped by a median
of 26 cells/mm
3, whereas it increased by 54 cells/mm
3 in the
group that added raltegravir (p=0.066 for the comparison,
Wilcoxon rank sum test). When the treatment groups were
pooled, the median CD4 count change was an increase of 42 cells/
mm
3 during raltegravir intensification (95% CI 22 to 57 cells/
mm
3). There was also no significant change in CD8 cell count
during raltegravir intensification.
Effect of Raltegravir Intensification on T Cell Activation
Because HIV-1 replication is associated with elevated T cell
activation, we looked for a relationship between baseline activation
and HIV-1 RNA level. CD4 and CD8 cell activation was
determined by measuring the percentage of cells that expressed
both CD38 and HLA-DR. There was no association between
baseline HIV-1 RNA value by SCA and baseline T cell activation
(for example, r=0.08 for the correlation between HIV-1 RNA and
CD4+/CD38+/HLA-DR+ percentage; r=0.01 for the correlation
between HIV-1 RNA and CD8+/CD38+/HLA-DR+ percentage;
both p-values.0.6, Spearman rank correlation).
In addition, we evaluated the association between baseline T
cell activation and other participant characteristics. There was no
correlation between age and either CD4+/CD38+/HLA-DR+ or
CD8+/CD38+/HLA-DR+ percentage. The duration of virologic
suppression and pre-ART HIV-1 RNA level were also not
correlated with T cell activation.
We then examined whether raltegravir intensification affected
the level of CD8 and CD4 cell activation (Table 3), as might be
expected if adding the drug inhibits ongoing low-level viral
replication that is inducing T cell activation. At baseline, patients
in the raltegravir-first group had a median of 11% CD8+/
CD38+/HLA-DR+ cells and those in the placebo-first group had
a median of 16% CD8+/CD38+/HLA-DR+ cells. We found no
statistically significant difference in the CD8+/CD38+/HLA-DR+
Raltegravir Intensification and HIV
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There was also no significant difference between the two treatment
groups in the change in CD8+/CD38+/HLA-DR+ percentage
from baseline to week 12 (21% in the raltegravir-first group versus
0% in the placebo-first group, p=0.50, Wilcoxon rank sum test) or
from week 12 to week 24 (+2% in the group that crossed-over to
add placebo versus 23% in the group that crossed-over to add
raltegravir, p=0.35, Wilcoxon rank sum test). We performed a
similar analysis of the effect of raltegravir intensification on CD4
cell activation. At baseline, participants in both the raltegravir-
and placebo-first groups had a median of 7% CD4+/CD38+/
HLA-DR+ cells. We found no statistically significant difference in
Figure 3. No reduction in low-level residual viremia after raltegravir intensification. (A) HIV-1 RNA values in patients in the raltegravir-first
group (red diamonds) compared with participants in the placebo-first group (blue circles). Shaded areas designate time periods during which
participants were receiving raltegravir intensification. Open symbols represent results for which one or both single copy assay (SCA) determinations
were below the lower limit of quantification. Median SCA values at each time point are reported (horizontal bars). The average HIV-1 RNA level at
week 10/12—the primary endpoint of the study—did not differ significantly between the raltegravir-first and the placebo-first groups: median 1.2 vs.
1.7 copies/mL (p=0.55, Wilcoxon rank sum test). (B) Median HIV-1 RNA levels in participants adding raltegravir-first at week 0 and then crossing over
to placebo at week 12 (red solid line) compared with participants adding placebo-first at week 0 and then crossing over to raltegravir at week 12
(blue dashed line). The lines connect medians. The bars represent interquartile ranges (25
th and 75
th percentiles).
doi:10.1371/journal.pmed.1000321.g003
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groups at week 12 or 24. There was also no significant difference
between the two treatment groups in the change in CD4+/
CD38+/HLA-DR+ percentage from baseline to week 12 or from
week 12 to week 24.
We also evaluated whether raltegravir intensification reduced
the percentage of CD4 and CD8 cells that expressed CD38, as
might be expected if viral replication was decreased, but CD38
expression was not our primary measure of immune activation
because naı ¨ve T cells can express this marker in the absence of
activation [10,11,12]. At baseline, there was an inverse correlation
between age and CD4+/CD38+ percentage (r=20.31, p=0.03,
Spearman rank correlation). There was no association between
age and CD8+/CD38+ percentage (r=20.24, p=0.10, Spear-
man rank correlation). The median change in CD8+/CD38+
from pre-intensification to post-intensification—when data from
the two treatment groups were pooled—was 22.0% (95% CI
210% to 0%) (p=0.046, Wilcoxon signed rank test). Although
there was a marginally significant difference between the groups in
the change in CD8+/CD38+ percent from baseline to week 12—
there was a median of a 3% decline in the group that added
raltegravir versus a 1% increase in the group that added placebo
(p=0.053 for the comparison, Wilcoxon rank sum test)—the
change in CD8+/CD38+ percentage from week 12 to 24 (after the
cross-over) did not differ between the treatment groups (Table 3).
We performed a similar analysis of the effect of intensification on
the percentage of CD4 cells that express CD38. When the two
treatment groups were pooled, the median percentage of cells
expressing CD38 decreased by 4% during the period of raltegravir
intensification (95% CI 29.5 to 20.5%, p=0.030, Wilcoxon
signed rank test). However, there was no significant difference
between the groups in the change in CD4+/CD38+ percentage
from baseline to week 12 (median 25% in the raltegravir-first
group versus 21% in the placebo-first group, p=0.10, Wilcoxon
rank sum test) or from week 12 to 24 (+1% in the group that
crossed-over to add placebo versus 22% in the group that crossed-
over to add raltegravir, p=0.82, Wilcoxon rank sum test) (Table 3).
Finally, to determine whether the trend toward an increase in
CD4 cell count during raltegravir intensification described above
could be explained by an effect on T cell activation, we analyzed
the relationship between change in activation markers and
increase in CD4 cell count. We found no associations between
Table 2. CD4 cell count changes in participants receiving immediate or delayed intensification with raltegravir.
Measure
Immediate Intensification
(Raltegravir-First)
Delayed Intensification
(Placebo-First) p-Value*
Baseline CD4 count (cells/mm
3) median (Q1, Q3) 538 (401, 717) 613 (454, 833) —
Change from baseline to week 12 (cells/mm
3) median (Q1, Q3) +42 (252, 80) 244 (2117, 49) 0.082
Change from week 12 to week 24 (cells/mm
3) median (Q1, Q3) 226 (254, 44) +54 (252, 144) 0.066
Quartile (Q)1 and Q3 are 25
th and 75
th percentiles.
*Wilcoxon rank sum test.
doi:10.1371/journal.pmed.1000321.t002
Table 3. Change in CD4 and CD8 activation by treatment group.
Measure Immediate Intensification (Raltegravir-First) Delayed Intensification (Placebo-First) p-Value*
CD8+CD38+HLA-DR+ Percentage
Baseline, median (Q1, Q3) 11 (8, 20) 16 (11, 20) —
Median change (Q1, Q3), baseline to week 12 21( 22, 2) 0( 22, 5) 0.50
Median change (Q1, Q3), week 12 to week 24 2 (21, 5) 23( 26, 5) 0.35
CD4+CD38+HLA-DR+ Percentage
Baseline, median (Q1, Q3) 7 (5, 9) 7 (6, 7) —
Median change (Q1, Q3), baseline to week 12 21( 22, 1) 0( 21, 2) 0.20
Median change (Q1, Q3), week 12 to week 24 1 (21, 3) 0( 23, 2) 0.18
CD8+CD38+ Percentage
Baseline, median (Q1, Q3) 39 (27, 50) 39 (34, 44) —
Median change (Q1, Q3), baseline to week 12 23( 211, 0) 1( 23, 7) 0.053
Median change (Q1, Q3), week 12 to week 24 0 (214, 11) 0( 214, 3) 0.36
CD4+CD38+Percentage
Baseline, median (Q1, Q3) 58 (49, 74) 60 (50, 67) —
Median change (Q1, Q3), baseline to week 12 25( 211, 0) 21( 26, 4) 0.10
Median change (Q1, Q3), week 12 to week 24 1 (217, 11) 22( 214, 4) 0.82
Our primary measure of CD8 activation was the CD8+CD38+HLA-DR+ percentage and of CD4 activation was the CD4+CD38+HLA-DR+ percentage (see text). Italicized
values designate a measurement was made during the period of raltegravir intensification.
Quartile (Q)1 and Q3 are 25
th and 75
th percentiles.
*Wilcoxon rank sum test.
doi:10.1371/journal.pmed.1000321.t003
Raltegravir Intensification and HIV
PLoS Medicine | www.plosmedicine.org 7 August 2010 | Volume 7 | Issue 8 | e1000321the changes in CD4 or CD8 CD38+/HLA-DR+ percentage or
CD38+ percentage and the trend towards a CD4 cell count
increase during raltegravir intensification (unpublished data).
Discussion
In this randomized, double-blind, placebo-controlled cross-over
study, 12 weeks of raltegravir intensification did not demonstrably
reduce residual viremia in patients on PI- or NNRTI-containing
ART. Although there was a trend toward an increased CD4 cell
count during the period of raltegravir intensification, this change
was not associated with an effect of raltegravir on T cell activation.
CD4 and CD8 cell activation levels in blood, as determined by the
percentage of CD38+/HLA-DR+ cells, were not associated with
the baseline level of residual viremia, and we did not find evidence
that raltegravir intensification reduced T cell activation by this
measure.
The findings of this study are consistent with the results of two
smaller, single-arm trials. In a study of treatment intensification
with 4–8 weeks of efavirenz, atazanavir/ritonavir or lopinavir/
ritonavir in nine HIV-1 infected patients, there was no effect of
adding the additional agent on HIV-1 RNA level measured by
SCA [5]. Similarly, in a study of ten patients, there was no
reduction in HIV-1 RNA level during 4 weeks of raltegravir
intensification [6]. In contrast, an earlier trial found that adding
abacavir reduced the level of HIV-1 RNA in patients receiving
indinavir plus efavirenz: of five patients with detectable viremia on
this two-drug regimen, four had a decline in viral RNA level after
adding abacavir [13]. However, the two-drug regimen of indinavir
plus efavirenz in this trial may not have blocked viral replication as
effectively as current three-drug combination ART, which could
explain why adding an agent lowered HIV-1 RNA in the early
study but not in more recent treatment intensification trials. The
results of the current trial are also consistent with other studies
which find that there is no evidence for substantive HIV-1
replication in patients on three-drug combination ART, as
assessed by the absence of viral evolution and the lack of
accumulation of drug resistance mutations [14,15].
A recently published study of raltegravir intensification has been
interpreted as showing that ongoing viral replication occurs in a
subset of patients on combination ART. Buzon et al. found that 13
of 45 (29%) patients on suppressive ART who were randomized to
add raltegravir had a transient increase in 2-LTR circles—an
episomal form of HIV DNA—which the authors interpret as
reflecting persistent replication [16]. Although the findings of this
study are important and provocative, its implications for
understanding the effect of intensification on viral replication are
uncertain for several reasons. First, of the 13 participants in whom
2-LTR circles were affected by raltegravir, five had detectable
circles even before adding the drug, whereas none of the control
patients had detectable 2-LTR circles at baseline, suggesting that
the treatment groups may have differed at the outset of the study.
Second, patients with prior antiretroviral treatment failure, who
might have less complete viral suppression, were enrolled in the
Buzon study, whereas such individuals were excluded from our
study. Third, it is not clear why only a subset of individuals had an
increase in 2-LTR circles. Patients who had an increase in 2-LTR
circles may not have been on ART long enough to have achieved
stable virologic suppression: individuals who became 2-LTR
+ had
received suppressive ART for a shorter time (mean 3.5 6 standard
deviation (SD) of 2.5 years) than those who did not become 2-
LTR
+ (mean 5.2 6 SD 2.9 years) (p=0.075). In our study, patients
had been on suppressive ART for a mean of 5.6 6 SD 3 years
(median of 5.5 years). The fact that increases in 2-LTR circles
occurred mainly in patients who were on protease inhibitor-
containing regimens suggests a mechanistic explanation indepen-
dent of ongoing full cycles of viral replication, e.g., that the
accumulation of 2-LTR circles is related to the stage at which
different antiretroviral agents block HIV-1 rather than a reflection
of complete cycles of viral replication. Finally, in the Buzon study,
there was no effect of raltegravir intensification on plasma HIV-1
RNA levels, as measured by a single copy assay; this finding is the
same as the result we obtained. The absence of an effect on plasma
HIV-1 RNA implies that raltegravir intensification does not
reduce ongoing viral replication, unless the virus is replicating in a
compartment that does not communicate freely with the plasma.
Studies to address this possibility by measuring the effect of
raltegravir intensification on important anatomic compartments,
such as gut-associated lymphoid tissue, are ongoing.
In addition to examining the effect of raltegravir intensification
on residual viremia, we examined the immunologic effects of this
intervention. Because residual viremia might affect immune
recovery, perhaps by triggering abnormal T cell activation and
increasing activation-induced cell death, we assessed whether
raltegravir intensification affected the CD4 cell count. We
observed an increase in CD4 cell count during the period of
raltegravir intensification. A raltegravir-based regimen was also
previously found to be associated with greater CD4 cell count
gains than an efavirenz-based regimen in a randomized study
conducted in treatment-naı ¨ve patients [8]. However, the increased
CD4 cell counts during raltegravir intensification in the current
study did not reach statistical significance and were not associated
with a decrease in T cell activation; therefore, the CD4 cell rise
may have been due to chance and should be interpreted
cautiously. The change in CD4 cell count may be due to an
action of raltegravir in a cellular or anatomic compartment that
affects T cell homeostasis but does not influence plasma viremia or
level of T cell activation in the blood; however, such a mechanism
is speculative.
This study also allowed us to examine the relationship between
residual viremia and T cell activation. Persistent viremia might
explain the observation that T cell activation remains higher in
patients who are receiving therapy and have HIV-1 RNA levels of
,50 copies/mL than in uninfected individuals [17]. This
persistent immune activation may have important clinical
consequences; for example, persistent T cell activation is
associated with lower CD4 cell count increases in patients
receiving ART [17,18,19] and may contribute to accelerated
atherosclerosis [20] or premature immunosenescence. If residual
viremia is inducing T cell activation, one might expect a
correlation between the level of viremia and extent of activation.
However, in those participants who had detectable residual
viremia, we did not find any associations between HIV-1 RNA
level at study entry and markers of T cell activation. In addition,
raltegravir intensification did not clearly decrease immune
activation in the blood, as measured by the percentage of T cells
that express CD38 and HLA-DR.
There are some potential limitations of our study. First, the
duration of raltegravir intensification was 12 weeks, which may not
have been long enough to see an effect of the agent on very long-
lived reservoirs. However, if residual viremia arises from new
cycles of infection, as opposed to release of virus from stable
reservoirs, we would expect to detect an effect on HIV-1 RNA
within the 12-week period of intensification. If there is ongoing
HIV-1 replication, one would expect that both short- and long-
lived cells would be infected—it seems implausible that new
infection would only occur in long-lived cells—and, therefore,
blocking infection of short-lived cells by adding raltegravir should
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such an effect argues that residual plasma viremia does not
primarily arise from complete cycles of HIV-1 replication and
infection of new cells. A second limitation of our study is that the
low HIV-1 RNA levels at study entry limit the ability to detect
declines after intensification; as a result, our findings do not
completely exclude the possibility that ongoing cycles of HIV-1
replication contribute to residual viremia. However, if adding
raltegravir substantially reduced HIV-1 replication and residual
viremia, we would expect that a higher proportion of patients
would have HIV-1 RNA levels below the detection level of the
single copy assay during intensification; we did not see such an
effect. Finally, as noted above, we cannot exclude the possibility
that there is ongoing viral replication in a compartment or
compartments that do not contribute to plasma viremia and do
not affect the level of T cell activation in blood. Studies of HIV-1
replication in other compartments, such as the gut-associated
lymphoid tissue, are required to exclude this possibility.
This study also has several strengths. First, unlike previous
single-arm intensification studies, we performed a double-blind
placebo-controlled randomized trial, which limits confounding.
Second, this study has a longer period of intensification than a
recently published trial that examined the effect of 4 weeks of
raltegravir intensification [6]. Third, the sample size of the current
study allows us to potentially detect smaller effects of intensifica-
tion on HIV-1 RNA, CD4 cell counts and immune activation
than previous smaller single-arm studies could discern. We were
able to exclude, with 95% confidence, a median reduction in
HIV-1 RNA during raltegravir intensification of more than 0.5
copies/mL in our population. Finally, the cross-over design of
the current study made it possible to conduct within-group com-
parisons of HIV-1 RNA levels before and after raltegravir
intensification; the lack of an effect when the drug was either
added or subtracted from the regimen strengthens confidence in
our results.
In conclusion, in this randomized, double-blind cross-over
study, 12 weeks of raltegravir intensification was not found to
reduce low-level plasma viremia in patients on currently rec-
ommended ART. This finding argues against the hypothesis that
ongoing, complete cycles of viral replication and integration are
the main source of residual viremia. These results suggest that
treatment intensification with raltegravir is unlikely to lead to
eradication of HIV-1 infection, and that new therapeutic strategies
to eliminate cellular or anatomic reservoirs will be required to cure
HIV-1 infection [4,21].
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Background. Acquired immunodeficiency syndrome (AIDS)
has killed about 25 million people since 1981 and more than
30 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV is a
retrovirus—its genetic blueprint is made of ribonucleic acid
(RNA). HIV infects human immune system cells and destroys
them, leaving infected individuals susceptible to other
infections. Early during the AIDS epidemic, most HIV-
positive people died within ten years of infection. Then, in
1996, effective antiretroviral therapy (ART) was developed.
ART consists of combinations of drugs that prevent viral
replication by inhibiting essential viral enzymes such as
reverse transcriptase (the enzyme that makes a DNA copy of
the viral RNA; a viral enzyme called integrase inserts this DNA
copy into the host cell DNA where it remains dormant until
the host cell is activated) and protease (an enzyme needed
for the production of new viral particles, which are released
into the blood stream). Now, in industrialized countries, the
life expectancy of HIV-infected patients treated with ART is
similar to that of people with diabetes and other chronic
conditions.
Why Was This Study Done? Although ART can reduce the
number of viral RNA copies in the plasma (the liquid portion
of blood) of HIV-positive patients to less than 50 copies/mL
(the limit of detection of commercial assays), it is does not
eradicate HIV. When very sensitive assays are used to detect
viral RNA (for example, the ‘‘single copy assay’’ or SCA), most
patients on ART have one copy or more of HIV RNA per mL
of plasma. The origin of this low-level residual viremia (virus
in the blood) is controversial. Residual viremia could arise
from ongoing cycles of viral replication, in which case
intensification of ART should reduce it. Alternatively, residual
viremia could be due to HIV release from stable reservoirs
such as latently infected resting immune system cells, in
which case intensification of ART should have no effect on
residual viremia. In this randomized, controlled trial (a study
in which randomly selected groups of patients are given
different treatments and the effects of these treatments
compared), the researchers assess whether the addition of
raltegravir (a drug that inhibits HIV integrase) to standard
ART has any effect on residual viremia.
What Did the Researchers Do and Find? The researchers
enrolled 53 HIV-positive patients who had been receiving
ART containing several reverse transcriptase inhibitors and,
in some cases, a protease inhibitor for at least 12 months and
who had a plasma HIV RNA level below 50 copies/mL but
detectable viremia by SCA. The patients were randomly
assigned to receive either raltegravir or a dummy drug
(placebo) in addition to their normal ART for 12 weeks. They
were then crossed-over (swapped) to the other therapy for a
further 12 weeks. At baseline, the trial participants had an
average plasma HIV RNA level of 1.7 copies/mL. The HIV RNA
level at weeks 10/12 (the average of SCA results at 10 and 12
weeks) was similar in the raltegravir group and in the
placebo group and did not differ significantly from this
baseline level. There was also no significant change in
plasma HIV RNA levels from weeks 10/12 to weeks 22/24
after the patients crossed-over between treatment groups.
What Do These Findings Mean? In this randomized,
cross-over study, raltegravir intensification of ART for 12
weeks did not demonstrably reduce low-level residual
viremia in HIV-positive patients receiving standard ART. It is
possible that 12 weeks is too short a time to see an effect of
raltegravir on residual viremia. Furthermore, although this is
one of the biggest trials of this type done to date, it might be
that insufficient patients were included in the trial to detect a
subtle effect of raltegravir on residual viremia. Nevertheless,
these findings argue against the hypothesis that residual
viremia arises from ongoing cycles of viral replication and the
infection of new cells. Instead, they suggest that residual
viremia might be due to the release of HIV from stable
reservoirs. If so, new therapeutic strategies designed to
eliminate these reservoirs of latently infected cells will be
required to cure HIV infection.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000321.
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS,
and on the treatment of HIV
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS, including information on antiretroviral therapies
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including the
treatment of HIV and AIDS (in English and Spanish)
N MedlinePlus has links to further resources on AIDS and on
AIDS medicines (in English and Spanish)
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